RCKT — Rocket Pharmaceuticals Cashflow Statement
0.000.00%
Last trade - 00:00- $359.30m
- $157.81m
Annual cashflow statement for Rocket Pharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -140 | -169 | -222 | -246 | -259 |
| Depreciation | |||||
| Non-Cash Items | 48.9 | 45.9 | 31.4 | 30.1 | 37.7 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 15 | -3.39 | 6.08 | 13.5 | 1.92 |
| Change in Prepaid Expenses | |||||
| Change in Accrued Expenses | |||||
| Change in Payable / Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -74.6 | -121 | -178 | -195 | -210 |
| Capital Expenditures | -29.1 | -7.71 | -8.62 | -16.5 | -5.86 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | -67.5 | 26.6 | -60.7 | -81.6 | 138 |
| Sale of Business | |||||
| Sale of Fixed Assets | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | -96.6 | 18.9 | -69.3 | -98.1 | 132 |
| Financing Cash Flow Items | -0.851 | 0 | 0 | — | — |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 283 | 37.7 | 155 | 208 | 186 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 112 | -64.6 | -92.2 | -84.6 | 108 |